Ovarian ablation followed by tamoxifen with or without 4 cycles of AC as adjuvant therapy for premenopausal women, node positive, hormone receptor positive breast cancer patients who are suitable for endocrine therapy alone.

Study Chairs
Prof. Beat Thürlimann - St. Gallen, Switzerland
Prof. Monica Castiglione - Bern, Switzerland

Statistician
Karen Price

Lead Trial Coordinator
Holly Shaw

Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
May 1, 1993

Date of Closure
November 1, 1998

Targeted Accrual
400 patients

Final Accrual
174 patients

Date of Discontinued Follow-up
December 31, 2011

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login